January 2026 in “Nutrición Hospitalaria” In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.
32 citations
,
November 2011 in “Reproductive Sciences” The study found that among young Brazilian women, the likelihood of metabolic syndrome in those with PCOS is strongly associated with BMI and the phenotype involving menstrual irregularity and hyperandrogenism.
4 citations
,
May 2014 in “European Journal of Dermatology” This study found that severe androgenetic alopecia was associated with metabolic syndrome components in male psoriatic patients, particularly those over 59 years old, suggesting the need for regular screening.
5 citations
,
May 2018 in “Therapeutic advances in drug safety” This review discusses the role of androgen therapy and neurosteroids in cerebrovascular health, highlighting the potential risks and benefits and the importance of pharmacogenetic testing, but reports no new experimental results.
June 2026 in “Frontiers in Medicine” This study conducted a large-scale comparison using FAERS data to assess the post-marketing safety profiles of spironolactone, eplerenone, and finerenone, finding unique adverse event patterns for each drug and highlighting the need for personalized safety monitoring and further investigation in other pharmacovigilance databases.
